- PROFESSOR | Medicine, Liver Diseases
- Liver Medicine
- Liver Transplantation
- Indian (Hindi)
- Urdu (Pakistan)
- Hospital Affiliation
- The Mount Sinai Hospital
Dr. Ahmad graduated with his medical degree with honors from the Royal Free Hospital School of Medicine, University of London. He completed post-graduate internal medicine training in the United Kingdom. He completed internal medicine and chief residency at the State University of New York at Stony Brook and gastroenterology and hepatology fellowship at the University of Pittsburgh. He previously served as the Chief of the GI Section at the Veterans’ Affairs Pittsburgh Healthcare System and was Co-Medical Director of Transplant Hepatology at the Thomas E. Starzl Transplantation Institute in Pittsburgh. Dr. Ahmad has published widely in the fields of hepatology and transplant hepatology. His main research interests include organ allocation and recurrent disease after liver transplantation.
American Board of Internal Medicine
- Endoscopic Band Ligation
- Esophageal Varices
- Hepatitis B
- Hepatitis C
- Liver Biopsy
- Liver Transplant
- Toxic Hepatitis
- Upper GI Endoscopy
MD, Royal Free Hospital Sch of Medicine
Residency, Internal Medicine
SUNY at Stony Brook School of Medicine
Fellowship, Gastroenterology & Hepatology
University of Pittsburgh Medical Center
English, Indian (Hindi), Urdu (Pakistan)
Dr Jawad Ahmad is co Primary Investigator on NIH/NIDDK research initiative to study cases of severe liver injury caused by caused by prescription drugs, over-the-counter drugs, and alternative medicines, such as herbal products and supplements. For more information on the Drug-Induced Liver Injury Network (DILIN) visit: https://dilin.dcri.duke.edu/
A Phase 2 Proof of Concept Study Investigating the Preliminary Efficacy and Safety of Cenicriviroc in Adult Subjects with Primary Sclerosing Cholangitis (PSC)
The purpose of this study is to look at the safety and effectiveness of the study drug cenicriviroc (CVC) and how well it works for the treatment of Primary Sclerosing Cholangitis (PSC). CVC is an investigational drug. This means that CVC is still being studied. It also means tha...
Ahmad J, Eng FJ, Branch AD. HCV and HCC: Clinical Update and a Review of HCC-Associated Viral Mutations in the Core Gene. Seminars in liver disease 2011 Nov; 31(4).
Sundaram V, Jones DT, Shah NH, de Vera ME, Fontes P, Marsh JW, Humar A, Ahmad J. Posttransplant biliary complications in the pre- and post-model for end-stage liver disease era. Liver transplantation 2011 Apr; 17(4).
Mounzer R, Malik SM, Nasr J, Madani B, Devera ME, Ahmad J. Spontaneous bacterial peritonitis before liver transplantation does not affect patient survival. Clinical gastroenterology and hepatology 2010 Jul; 8(7).
Malik SM, Devera ME, Fontes P, Shaikh O, Sasatomi E, Ahmad J. Recurrent disease following liver transplantation for nonalcoholic steatohepatitis cirrhosis. Liver transplantation 2009 Dec; 15(12).
Malik SM, deVera ME, Fontes P, Shaikh O, Ahmad J. Outcome after liver transplantation for NASH cirrhosis. American journal of transplantation 2009 Apr; 9(4).
Malik SM, Gupte PA, de Vera ME, Ahmad J. Liver transplantation in patients with nonalcoholic steatohepatitis-related hepatocellular carcinoma. Clinical gastroenterology and hepatology 2009 Jul; 7(7).
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Ahmad did not report having any of the following types of financial relationships with industry during 2016 and/or 2017: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.